Research On Performance Evaluation Of Listed Companies In Biopharmaceutical Industry

With the biopharmaceutical industry gradually becoming the focus of the world development competition,China pays more and more attention to the development of biopharmaceutical industry.At present,the biopharmaceutical industry is in a favorable development condition in China.The government's subsidies to the industry,the introduction of various preferential policies and the potential huge market have formed favorable support for the development of the biopharmaceutical industry.However,there are many problems in the biopharmaceutical industry.Due to the high standards and requirements of products,the low transformation rate of industrial scientific and technological achievements may occur Product quality problems,enterprise operation difficulties and other issues.Therefore,it is necessary to explore and analyze the performance level of Listed Companies in China's biopharmaceutical industry.This paper summarizes the research of domestic and foreign scholars,analyzes the current situation of biopharmaceutical industry,based on the theory of sustainable development,according to the characteristics and development strategy of biopharmaceutical industry,combined with the balanced scorecard,from the four angles of finance,customers,internal process,learning and growth,establishes the specific strategic objectives of Biopharmaceutical Enterprises,and constructs 19 indicators of health Performance evaluation index system of Listed Companies in the pharmaceutical industry.Through the comparative analysis of enterprise performance evaluation methods,in order to analyze the common characteristics of Biopharmace-utical Enterprises and find out the problems existing in the development of each enterprise,this paper determines the evaluation method which combines the gray correlation analysis method and cluster analysis.Based on the data of 21 listed companies in China's biopharmaceutical industry from 2016 to 2018,entropy weight method is used to calculate the weight of each index,and gray correlation method is used to carry out vertical and horizontal comparative analysis of each enterprise's performance.After calculating the horizontal performance scores of each enterprise,cluster analysis method is used to classify 21 listed companies in biopharmaceutical industry.Through the empirical analysis,the final conclusion is:the general performance level of biopharmaceutical companies is not high,and the competition is fierce;the development of customer dimension and internal process dimension has a great impact on the performance level of biopharmaceutical companies;the development of biopharmaceutical companies in many aspects is uneven,and there are short boards of ability;biopharmaceutical companies are deeply affected by industry policies;and all enterprises The degree of fulfillment of social responsibility needs to be raised to the height of strategic objectives.It shows that there are still many problems in the development of Biopharmaceutical Enterprises,and the performance level of the whole industry needs to be improved.Finally,the paper puts forward suggestions on how to improve the performance level of Biopharmaceutical Enterprises,in order to provide reference for future scholars to study the performance evaluation of biopharmaceutical industry.